Recent Updates
Recently added Catalysts

Urothelial Cancer: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.4Buniverse median $1.20B
Allocated capital$1.4B$1.4B competing
Phase 3 or filed00 mid, 1 early
Pure plays1this indication only
Capital rank121/299crowding rank 140

Urothelial Cancer is uncontested. Aktis Oncology (AKTS) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Ac-AKY-1189 in phase 1.

There is no public comparable to price it against, and AKTS runs clinical programmes in this indication and nothing else, so its $1.4B market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$1.4B of allocated capital sits in Urothelial Cancer, ranking it 121st of 299 indications by the money committed to it.

Companies developing drugs for Urothelial Cancer 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AKTSAktis OncologyAc-AKY-1189Phase 12$1.4BYes1 31 Mar 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Urothelial Cancer counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Urothelial Cancer has one competitor and a median of $1.4B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Soft-tissue Sarcoma2 companies · $1.5B · median $4.0BConcentrated betMetastatic Small Cell Lung Cancer1 company · $1.3B · median $4.0BUncontestedAdvanced Renal Cell Carcinoma1 company · $1.3B · median $14.7BUncontestedCastrate-resistant Prostate Cancer1 company · $1.3B · median $14.7BUncontestedHead and Neck Neoplasms1 company · $1.3B · median $14.7BUncontestedPancreatic Neuroendocrine Tumors1 company · $1.3B · median $14.7BUncontestedIntrahepatic Cholangiocarcinoma1 company · $1.5B · median $6.1BUncontestedGastrointestinal Cancer1 company · $1.5B · median $6.1BUncontested

Urothelial Cancer pipeline questions

Which biotech companies are developing drugs for Urothelial Cancer?

Aktis Oncology (AKTS, Ac-AKY-1189, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Urothelial Cancer.

How advanced is the Urothelial Cancer pipeline?

Of the 1 clinical-stage programme in Urothelial Cancer, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Urothelial Cancer?

No. AKTS is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Urothelial Cancer, which is why the indication is classified as uncontested.

When is the next Urothelial Cancer catalyst?

The next dated catalyst in Urothelial Cancer is AKTS on 31 Mar 2027. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map